Last reviewed · How we verify

Pegvaliase-Pqpz — Competitive Intelligence Brief

Pegvaliase-Pqpz (Pegvaliase-Pqpz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Metabolic/Genetic disorder.

marketed Enzyme replacement therapy Phenylalanine (substrate); phenylalanine ammonia lyase (active enzyme) Metabolic/Genetic disorder Small molecule Live · refreshed every 30 min

Target snapshot

Pegvaliase-Pqpz (Pegvaliase-Pqpz) — University of Missouri-Columbia. Pegvaliase-pqpz is a pegylated phenylalanine ammonia lyase that catalytically degrades phenylalanine to reduce blood phenylalanine levels in patients with phenylketonuria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pegvaliase-Pqpz TARGET Pegvaliase-Pqpz University of Missouri-Columbia marketed Enzyme replacement therapy Phenylalanine (substrate); phenylalanine ammonia lyase (active enzyme)
alpha-1-Proteinase Inhibitor alpha-1-Proteinase Inhibitor Institute for Human Genetics and Biochemistry marketed Protease inhibitor / Enzyme replacement therapy Neutrophil elastase
Naglazyme® Naglazyme® Masonic Cancer Center, University of Minnesota marketed Enzyme replacement therapy Arylsulfatase B (ARSB)
Elelyso Taliglucerase Alfa Pfizer Inc. marketed Enzyme replacement therapy Glucocerebroside (substrate); mannose receptors on cell surface
Cerezyme® / Imiglucerase Cerezyme® / Imiglucerase Sanofi marketed Enzyme replacement therapy Glucocerebrosidase (β-glucosidase)
Fabrazyme (agalsidase beta) Fabrazyme (agalsidase beta) Genzyme, a Sanofi Company marketed Enzyme replacement therapy (ERT); recombinant enzyme α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)
agalsidase beta (GZ419828) agalsidase beta (GZ419828) Sanofi marketed Enzyme replacement therapy Alpha-galactosidase A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme replacement therapy class)

  1. BioMarin Pharmaceutical · 5 drugs in this class
  2. Sanofi · 3 drugs in this class
  3. JCR Pharmaceuticals Co., Ltd. · 2 drugs in this class
  4. Genzyme, a Sanofi Company · 2 drugs in this class
  5. Pfizer Inc. · 1 drug in this class
  6. Shire · 1 drug in this class
  7. Alexion Pharmaceuticals, Inc. · 1 drug in this class
  8. University of Missouri-Columbia · 1 drug in this class
  9. Eurofarma Laboratorios S.A. · 1 drug in this class
  10. ISU Abxis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegvaliase-Pqpz — Competitive Intelligence Brief. https://druglandscape.com/ci/pegvaliase-pqpz. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: